Development of small molecule antagonists of HGF/SF and MET signalling to treat metastatic cancer [ 2014 - 2018 ]

Research Grant

Researchers: Dr David Ascher (Principal investigator)

Brief description The spread of cancer throughout the body, metastasis, is the major cause of death from cancer. The MET receptor plays a crucial role in over 60% of all metastases and several approaches to block its activity are currently in clinical trials. This project will use a new approach to develop small molecule inhibitors that block the MET receptor from interacting with another protein, HGF/SF. Small molecules that block this interaction will be highly effective treatments against metastatic cancers.

Funding Amount $AUD 353,866.28

Funding Scheme Early Career Fellowships

Notes CJ Martin Biomedical ECF